Dhananjay Kapse
Overview
Explore the profile of Dhananjay Kapse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
103
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diallo F, Haidara F, Tapia M, Dominguez Islas C, Alderson M, Hausdorff W, et al.
Lancet
. 2025 Mar;
PMID: 40086461
Background: Invasive meningococcal disease is a devastating public health problem for the African meningitis belt. We assessed the safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A,...
2.
Kulkarni P, Kawade A, Kohli S, Munshi R, Maliye C, Gogtay N, et al.
Lancet Infect Dis
. 2024 Nov;
PMID: 39521012
Background: Meningococcal disease remains an important public health problem globally. We assessed the non-inferiority and the lot-to-lot consistency of a pentavalent meningococcal ACYWX conjugate vaccine (NmCV-5; Serum Institute of India,...
3.
Kulkarni P, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M, Kulkarni P, et al.
Hum Vaccin Immunother
. 2024 Mar;
20(1):2304974.
PMID: 38512394
AZD1222 (ChAdOx1 nCoV-19) is a replication-deficient adenoviral vectored coronavirus disease-19 (COVID-19) vaccine that is manufactured as SII-ChAdOx1 nCoV-19 by the Serum Institute of India Pvt Ltd following technology transfer from...
4.
Kulkarni P, Gunale B, Kohli S, Lalwani S, Tripathy S, Kar S, et al.
Sci Rep
. 2023 Oct;
13(1):16579.
PMID: 37789040
Due to waning immunity following primary immunization with COVID-19 vaccines, booster doses may be required. The present study assessed a heterologous booster of SII-NVX-CoV2373 (spike protein vaccine) in adults primed...
5.
Gunale B, Kapse D, Kar S, Bavdekar A, Kohli S, Lalwani S, et al.
JAMA Pediatr
. 2023 Jul;
PMID: 37523166
Importance: The recombinant COVID-19 vaccine NVX-CoV2373 has demonstrated efficacy of approximately 90% in adults; however, its safety and efficacy in children is unknown. Objective: To assess the noninferiority of SII-NVX-CoV2373...
6.
Kang G, Lakhkar A, Bhamare C, Dharmadhikari A, Narwadkar J, Kanujia A, et al.
Lancet Reg Health Southeast Asia
. 2023 Jul;
14:100207.
PMID: 37492421
Background: A vero cell-based inactivated Rabies Vaccine (Rabivax-S) and Rabies Human Monoclonal Antibody (Rabishield) have been approved since 2016. A post-marketing surveillance was conducted in India from 2020 to 2021...
7.
Haidara F, Umesi A, Sow S, Ochoge M, Diallo F, Imam A, et al.
N Engl J Med
. 2023 May;
388(21):1942-1955.
PMID: 37224196
Background: An effective, affordable, multivalent meningococcal conjugate vaccine is needed to prevent epidemic meningitis in the African meningitis belt. Data on the safety and immunogenicity of NmCV-5, a pentavalent vaccine...
8.
Kulkarni P, Kadam A, Godbole S, Bhatt V, Raut A, Kohli S, et al.
Lancet Reg Health Southeast Asia
. 2023 Jan;
10:100139.
PMID: 36647543
Background: NVX-CoV2373, a Covid-19 vaccine was developed in the USA with ∼90% efficacy. The same vaccine is manufactured in India after technology transfer (called as SII-NVX-CoV2373), was evaluated in this...
9.
Cotton M, Madhi S, Luabeya A, Tameris M, Hesseling A, Shenje J, et al.
Lancet Infect Dis
. 2022 Jun;
22(10):1472-1483.
PMID: 35772447
Background: Tuberculosis is a major public health problem worldwide. Immunisation with Mycobacterium bovis BCG vaccine is partially effective in infants, reducing the incidence of miliary and tuberculosis meningitis, but is...
10.
Kulkarni P, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M, Kulkarni P, et al.
EClinicalMedicine
. 2021 Dec;
42:101218.
PMID: 34870133
Background: This phase 2/3 immunobridging study evaluated the safety and immunogenicity of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) (SII-ChAdOx1 nCoV-19), manufactured in India at the Serum Institute of India Pvt...